Evaluation of Nanocarrier Targeted Drug Delivery of Capecitabine-PAMAM Dendrimer Complex in a Mice Colorectal Cancer Model
Capecitabine, an effective anticancer drug in colorectal cancer chemotherapy, may create adverse side effects on healthy tissues. In the present study, we first induced colon adenocarcinoma with azoxymethane, a carcinogen agent, and then investigated the potentiality of polyamidoamine (PAMAM) dendrimer to improve capecitabine therapeutic index and decrease its adverse side effects on healthy tissues like liver and bone marrow. Other variables such as nanoparticle concentrations have also been investigated. Drug loading concentration (DLC) and encapsulation efficiency (EE) were calculated for capecitabine/dendrimer complex. Experimental results showed an increase in DLC percentage resulted from elevated capecitabine/dendrimer ratio. Capecitabine/dendrimer complex could reduce tumor size and adverse side effects in comparison with free capecitabine form.
Siegel, R., D. Naishadham, and A. Jemal, Cancer statistics, 2013. CA Cancer J Clin, 2013. 63(1): p. 11-30.
Fearon, E.R. and B. Vogelstein, A genetic model for colorectal tumorigenesis. Cell, 1990. 61(5): p. 759-67.
Purim, O., N. Gordon, and B. Brenner, Cancer of the colon and rectum: potential effects of sex-age interactions on incidence and outcome. Med Sci Monit, 2013. 19: p. 203-9.
Askling, J., et al., Family history as a risk factor for colorectal cancer in inflammatory bowel disease. Gastroenterology, 2001. 120(6): p. 1356-62.
Giovannucci, E., An updated review of the epidemiological evidence that cigarette smoking increases risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev, 2001. 10(7): p. 725-31.
Le Marchand, L., et al., Associations of sedentary lifestyle, obesity, smoking, alcohol use, and diabetes with the risk of colorectal cancer. Cancer Res, 1997. 57(21): p. 4787-94.
Triantafillidis, J.K., G. Nasioulas, and P.A. Kosmidis, Colorectal cancer and inflammatory bowel disease: epidemiology, risk factors, mechanisms of carcinogenesis and prevention strategies. Anticancer Res, 2009. 29(7): p. 2727-37.
Bansal, P. and A. Sonnenberg, Risk factors of colorectal cancer in inflammatory bowel disease. Am J Gastroenterol, 1996. 91(1): p. 44-8.
Meissner, H.I., et al., Patterns of colorectal cancer screening uptake among men and women in the United States. Cancer Epidemiol Biomarkers Prev, 2006. 15(2): p. 389-94.
Drasar, B.S. and D. Irving, Environmental factors and cancer of the colon and breast. Br J Cancer, 1973. 27(2): p. 167-72.
Yun, H.R., et al., Adjuvant chemotherapy increase survival and decrease recurrence in stage IIA colon cancer. Hepatogastroenterology, 2012. 59(120): p. 2466-71.
Reibetanz, J. and C.T. Germer, [Neoadjuvant chemotherapy for locally advanced colon cancer : Initial results of the FOxTROT study.]. Chirurg, 2013.
Deng, T., et al., Bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as the second-line therapy for patients with metastatic colorectal cancer, a multicenter study. Med Oncol, 2013. 30(4): p. 752.
Coskun, U., et al., Xelox (capecitabine plus oxaliplatin) as neoadjuvant chemotherapy of unresectable liver metastases in colorectal cancer patients. Neoplasma, 2008. 55(1): p. 65-70.
Goldberg, R.M., et al., A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol, 2004. 22(1): p. 23-30.
Ku, G.Y., G. De Lima Lopes, Jr., and A.Y. Chang, Bevacizumab in combination with oxaliplatin and doxorubicin or liposomal doxorubicin for hepatocellular cancer: a case series. Asia Pac J Clin Oncol, 2011. 7(2): p. 174-9.
Vamvakas, L., et al., Capecitabine in combination with oxaliplatin and bevacizumab (AXELOX) as 1st line treatment for fit and vulnerable elderly patients (aged >70 years) with metastatic colorectal cancer (mCRC): a multicenter phase II study of the Hellenic Oncology Research Group (HORG). BMC Cancer, 2014. 14: p. 277.
O'Shaughnessy, J.A., Potential of capecitabine as first-line therapy for metastatic breast cancer: dosing recommendations in patients with diminished renal function. Ann Oncol, 2002. 13(6): p. 983.
Ishitsuka, H., Capecitabine: preclinical pharmacology studies. Invest New Drugs, 2000. 18(4): p. 343-54.
Richardson, J.L., G. Marks, and A. Levine, The influence of symptoms of disease and side effects of treatment on compliance with cancer therapy. J Clin Oncol, 1988. 6(11): p. 1746-52.
Maslov, M.Y., et al., High concentrations of drug in target tissues following local controlled release are utilized for both drug distribution and biologic effect: an example with epicardial inotropic drug delivery. J Control Release, 2013. 171(2): p. 201-7.
Najlah, M. and A. D'Emanuele, Synthesis of dendrimers and drug-dendrimer conjugates for drug delivery. Curr Opin Drug Discov Devel, 2007. 10(6): p. 756-67.
Minagawa, K., et al., Target delivery and controlled release of the chemopreventive drug sulindac by using an advanced layered double hydroxide nanomatrix formulation system. J Mater Sci Mater Med, 2012. 23(4): p. 973-81.
Langer, R., Drug delivery. Drugs on target. Science, 2001. 293(5527): p. 58-9.
Falciani, C., et al., Target-selective drug delivery through liposomes labeled with oligobranched neurotensin peptides. ChemMedChem, 2011. 6(4): p. 678-85.
Patri, A.K. and E. Simanek, Biological applications of dendrimers. Mol Pharm, 2012. 9(3): p. 341.
Lee, C.C., et al., Designing dendrimers for biological applications. Nat Biotechnol, 2005. 23(12): p. 1517-26.
Cloninger, M.J., Biological applications of dendrimers. Curr Opin Chem Biol, 2002. 6(6): p. 742-8.
Duncan, R., Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer, 2006. 6(9): p. 688-701.
Maeda, H. and Y. Matsumura, EPR effect based drug design and clinical outlook for enhanced cancer chemotherapy. Adv Drug Deliv Rev, 2011. 63(3): p. 129-30.
Keereweer, S., et al., Targeting integrins and enhanced permeability and retention (EPR) effect for optical imaging of oral cancer. J Surg Oncol, 2012. 105(7): p. 714-8.
Park, K., Questions on the role of the EPR effect in tumor targeting. J Control Release, 2013. 172(1): p. 391.
Fang, J., H. Nakamura, and H. Maeda, The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev, 2011. 63(3): p. 136-51.
Maeda, H., G.Y. Bharate, and J. Daruwalla, Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur J Pharm Biopharm, 2009. 71(3): p. 409-19.
Lammers, T., W.E. Hennink, and G. Storm, Tumour-targeted nanomedicines: principles and practice. Br J Cancer, 2008. 99(3): p. 392-7.
Esfand, R. and D.A. Tomalia, Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications. Drug Discov Today, 2001. 6(8): p. 427-436.
Liu, M. and J.M. Frechet, Designing dendrimers for drug delivery. Pharm Sci Technolo Today, 1999. 2(10): p. 393-401.
Kojima, C., et al., Synthesis of polyamidoamine dendrimers having poly(ethylene glycol) grafts and their ability to encapsulate anticancer drugs. Bioconjug Chem, 2000. 11(6): p. 910-7.
Albertazzi, L., et al., Synthesis, cellular delivery and in vivo application of dendrimer-based pH sensors. J Vis Exp, 2013(79).
Svenson, S. and D.A. Tomalia, Dendrimers in biomedical applications--reflections on the field. Adv Drug Deliv Rev, 2005. 57(15): p. 2106-29.
Daneshvar, N., et al., PAMAM dendrimer roles in gene delivery methods and stem cell research. Cell Biol Int, 2013. 37(5): p. 415-9.
Malik, N., et al., Dendrimers: relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo. J Control Release, 2000. 65(1-2): p. 133-48.
Labieniec, M., et al., Effect of poly(amido)amine (PAMAM) G4 dendrimer on heart and liver mitochondria in an animal model of diabetes. Cell Biol Int, 2010. 34(1): p. 89-97.
Wiwattanapatapee, R., et al., Anionic PAMAM dendrimers rapidly cross adult rat intestine in vitro: a potential oral delivery system? Pharm Res, 2000. 17(8): p. 991-8.
Derry, M.M., et al., Characterization of azoxymethane-induced colon tumor metastasis to lung in a mouse model relevant to human sporadic colorectal cancer and evaluation of grape seed extract efficacy. Exp Toxicol Pathol, 2014. 66(5-6): p. 235-42.
Weisburger, J.H., Proceedings: Chemical carcinogenesis in the gastrointestinal tract. Proc Natl Cancer Conf, 1972. 7: p. 465-73.
Pereira, M.A., et al., Use of azoxymethane-induced foci of aberrant crypts in rat colon to identify potential cancer chemopreventive agents. Carcinogenesis, 1994. 15(5): p. 1049-54.
Miyagi, Y., et al., Inhibition of azoxymethane-induced colon cancer by orange juice. Nutr Cancer, 2000. 36(2): p. 224-9.
Ward, J.M., Morphogenesis of chemically induced neoplasms of the colon and small intestine in rats. Lab Invest, 1974. 30(4): p. 505-13.
Ward, J.M., R.S. Yamamoto, and C.A. Brown, Pathology of intestinal neoplasms and other lesions in rats exposed to azoxymethane. J Natl Cancer Inst, 1973. 51(3): p. 1029-39.
|Issue||Vol 54, No 8 (2016)|
|Colorectal cancer Azoxymethane Capecitabine Polyamidoamine (PAMAM) dendrimer|
|Rights and permissions|
|This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.|